Positive Quality Intervention: VEGF Inhibitor-Induced Hypertension

Description: This document will address effective practices for the management of vascular endothelial growth factor inhibitors (VEGFIs) induced hypertension (HTN).

Background: VEGFIs are a growing therapeutic class that targets tumor angiogenesis to prevent metastasis and tumor progression.1 It has wide applicability in a variety of cancers including, brain, breast, colon, kidney, liver, lung, and rectal.2 Due to its mechanism of action, the VEGFIs are known to cause HTN. The activation of VEGF exerts a multifaceted effect on the vasculature, including enhanced endothelial permeability, vasodilation through the production of nitric oxide, and angiogenesis in physiologic processes like wound repair. VEGFIs clinically targets this process, often leading to a dose-dependent blood pressure (BP) increase as a side effect.3 A similar effect has also been observed in tyrosine kinase inhibitors with VEGFI activity.2 Incidence of VEGFI-related HTN varies from 30-80%, depending on the medication.1,3,4 Uncontrolled HTN and hypertensive crisis can necessitate dose reductions or therapy discontinuation, worsening patient outcomes.3 Strict blood pressure control and monitoring is required as BP can rise rapidly (within the first 24 hours of therapy initiation).1

PQI Process: Before initiating VEGFIs, patients should be evaluated for:

- Cardiovascular risk factors5-7
  - History of cardiovascular disease (CVD), diabetes, prior documentation of left ventricular hypertrophy, age, smoking, family history of early CVD
  - Physical examination: controlled blood pressure, waist circumference
  - Labs: serum creatinine, fasting blood glucose, lipid profile, urine albumin
  - Screening for end-organ damage
  - Socioeconomic barriers (health literacy, access to proper fitting cuff, ability to perform self-monitoring)

- Medications/drugs that may worsen HTN
  - Prescription Medications: NSAIDs, adrenal steroid hormones, erythropoietin, hormonal contraceptives, sympathomimetics
  - OTC: oxymetazoline, pseudoephedrine, phenylephrine, NSAIDs
  - Supplements: saw palmetto, St John’s wort, ephedra, DHEA, bitter orange, green coffee extract, kava

- During Treatment
  - Monitoring BP: Weekly clinic visits or documentation with a certified cuff device for at-home use in the first cycle; after that, check BP every 2-3 weeks.8 If antihypertensives are initiated, monitor for efficacy and adverse effects (see Table 2)
  - Initiate Antihypertensives: Initiate antihypertensives if BP >140/90 (>130/80 if high risk), or if DBP increases by >20 mmHg from baseline.6 HTN management should be guideline-directed, taking into account comorbidities and potential drug interactions (Table 2)6,9
  - Hold or D/C VEGFI: Refer to the package insert for drug-specific recommendations (Table 1), but in general, hold/discontinue (D/C)VEGFI if HTN is uncontrolled or if patient has malignant HTN or hypertensive crisis

IMPORTANT NOTICE: NCODA has developed this Positive Quality Intervention platform. This platform is intended as an educational aid, does not provide individual medical advice, and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication. The materials contained in this platform do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA. NCODA does not ensure the accuracy of the information presented and assumes no liability relating to its accuracy. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. It is the individual’s sole responsibility to seek guidance from a qualified healthcare professional. Updated 5.28.24
Agent | Package Insert Recommendations (HTN and proteinuria)
---|---
Bevacizumab | Routine blood pressure monitoring every 2-3 weeks, hold if SBP>160 mmHg or DBP>100 mmHg, and watch for signs of proteinuria
Ramucirumab | Routine blood pressure monitoring every 2 weeks or more as indicated
Ziv-aflibercept | Monitor blood pressure every 2 weeks or more frequently as indicated during treatment. Temporarily suspend if hypertension is not controlled and permanently reduce dose to 2 mg/kg for subsequent cycles. Withhold for more than 2 g of proteinuria in 24 hrs and D/C for nephrotic syndrome or thrombotic microangiopathy
Sorafenib | Monitor blood pressure weekly for the first 6 weeks, EKG and electrolytes for those at high risk of arrhythmias. If HTN: hold until symptoms resolve and DBP<90 mm Hg, then resume at reduced dose by 1 dose level. If needed, reduce another dose level.
Sunitinib | Monitor blood pressure and suspend administration in severe hypertension until controlled, monitor for proteinuria, signs of CHF
Pazopanib | Blood pressure should be well-controlled prior to initiating and D/C if hypertension is severe and persistent despite anti-hypertensive therapy, monitor urine protein and D/C for Grade 4 proteinuria, EKG for risk of QTc prolongation
Axitinib | Monitor for hypertension and reduce dose or D/C in the case of persistent hypertension despite medications or in the case of hypertensive crisis, monitor for proteinuria before initiation and periodically throughout and reduce dose or temporarily D/C if moderate to severe
Regorafenib | Monitor blood pressure weekly for the first 6 weeks and then every cycle or more frequently if indicated and temporarily or permanently hold for severe or uncontrolled hypertension
Ponatinib | Monitor and manage blood pressure elevations, monitor for signs of CHF, monitor for fluid retention and interrupt, reduce, or D/C if present
Vandetanib | Hypertension should be monitored and drug should not be restarted if blood pressure cannot be controlled, monitor for signs of HF, EKG for risk of QTc prolongation
Cabozantinib | Routine blood pressure monitoring and withhold if hypertension is not adequately controlled with antihypertensive therapy and restart at a lower dose. D/C if hypertensive crisis or severe hypertension that cannot be controlled, monitor urine protein and D/C for nephrotic syndrome
Lenvatinib | Check blood pressure at 1 week, then every 2 weeks for the first 2 months, then monthly. Withhold, dose-reduce, or D/C if hypertension is severe. Monitor for proteinuria prior to treatment and periodically. Withhold for more than 2 g of proteinuria in 24 hrs, and D/C for nephrotic syndrome

**Patient-Centered Activities:**
- Provide [Oral Chemotherapy/Intravenous Cancer Treatment Education](#) Sheets (Table 1 links)
- Record BP readings in a journal: include contingency plan in case of emergency
- Lifestyle modifications: exercise, dietary approaches to stop hypertension (DASH), avoid alcohol, cigarettes, and caffeine
- Connect patients to stress-reduction resources as needed

<table>
<thead>
<tr>
<th>Class</th>
<th>Examples</th>
<th>Application</th>
<th>Caution/Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACEs</td>
<td>Lisinopril, enalapril, quinapril, ramipril, fosinopril, benazepril, captopril</td>
<td>Pre-existing/high risk of left ventricular dysfunction</td>
<td>Coadministration of renally-cleared medications (cisplatin, pemetrexed, etc.) or in patients with hyperkalemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renovascular disease, peripheral vascular disease, renal impairment</td>
</tr>
<tr>
<td>ARBs</td>
<td>Valsartan, irbesartan, losartan, olmesartan, telmisartan, candesartan</td>
<td>Preferred first line in diabetes, proteinuria</td>
<td>Asthenia, malaise, fatigue, concomitant QTc-prolonging drugs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bradycardia/heart block, diabetes, asthma/COPD, decompensated CHF</td>
</tr>
<tr>
<td>β-blockers</td>
<td>Atenolol, bisoprolol, nadolol, propranolol (LA), metoprolol</td>
<td>Pre-existing/high risk of left ventricular dysfunction or history of MI, anxiety</td>
<td>Asthenia, malaise, fatigue, concomitant QTc-prolonging drugs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bradycardia/heart block, diabetes, asthma/COPD, decompensated CHF</td>
</tr>
<tr>
<td>CCB</td>
<td>Amlodipine, felodipine, nifedipine LA</td>
<td>Preferred in CKD on alkylating agents</td>
<td>Lower extremity edema</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Favorable for isolated systolic HTN</td>
<td>Avoid non-dihydropyridine CCBs (diltiazem and verapamil) with CYP3A4-metabolized chemotherapy (ex. sunitinib and sorafenib)</td>
</tr>
<tr>
<td>Thiazide diuretics</td>
<td>Chlorthalidone, HCTZ (± triamterene)</td>
<td>Patient on glucocorticoids (+ mineralocorticoid antagonists)</td>
<td>Risk of hypercalcemia or hypokalemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Favorable for isolated systolic HTN</td>
<td>Concomitant QTc-prolonging drugs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sulfa allergy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Acute kidney injury due to CINV dehydration</td>
</tr>
</tbody>
</table>

**References:**


5. Donald C. Moore, PharmD, BCPS, BCOP; Margaret M. Kientzel, PharmD; and Adenike Fasan, BPharm. Hypertension Caused by VEGF-Signaling Pathway Inhibitors. *Journal of Hematology Oncology Pharmacy*. 2017;7(4):141-143.


